Journey Medical Corporation — Form 8-K Summary
Business Context and Reporting Period
Journey Medical Corporation filed this Current Report on September 19, 2023, under Item 8.01 (Other Events). The filing concerns Nasdaq listing compliance and the effect of a recent licensing transaction on stockholders’ equity. It is not a quarterly financial report; the filing states that the quarter ended September 30, 2023, had not yet been closed.
Key Financial and Capitalization Matters
- Nasdaq previously notified the Company that it did not comply with Listing Rule 5550(b)(1), which requires at least $2.5 million of stockholders’ equity for continued listing on the Nasdaq Capital Market.
- The Company also did not meet the alternative requirements based on market value of listed securities or net income from continuing operations.
- Under its August 31, 2023 license agreement with Maruho Co., Ltd., the Company granted exclusive rights to develop and commercialize Qbrexza® for primary axillary hyperhidrosis in certain jurisdictions.
- Maruho paid the Company $19 million under the license agreement, among other consideration.
- Based on preliminary estimates and information available as of September 19, 2023, the Company believes the payment enables it to satisfy Nasdaq’s $2.5 million stockholders’ equity requirement.
- The filing does not provide clear values for revenue, net income, cash flow, margins, debt, cash balances, or liquidity.
Material Changes, Outlook, and Risks
- The Company had until September 29, 2023, to submit a compliance plan, if necessary. Nasdaq could grant an extension to regain compliance for no longer than February 11, 2024.
- The Company was awaiting Nasdaq’s formal compliance determination and stated that it would provide an update after receiving that determination.
- The stockholders’ equity assessment was preliminary, unaudited, and not reviewed or compiled by the Company’s independent registered public accounting firm.
- Quarter-end closing procedures were incomplete, and reported stockholders’ equity could change after completion of those procedures.
- The $19 million licensing payment is an unusual item and may materially affect stockholders’ equity, but the filing does not quantify its accounting impact on earnings, cash flow, or future revenue.
Important Facts for Investors to Verify
- Nasdaq’s formal determination regarding compliance with Listing Rule 5550(b)(1).
- Final stockholders’ equity reported after completion of the September 30, 2023 quarter-end close.
- The complete economic and accounting terms of the Maruho license agreement, including any milestones, royalties, restrictions, or contingent obligations.
- The effect of the licensing transaction on quarterly results, cash, taxes, and future Qbrexza® revenue.
- Whether any additional financing, capital-raising, or compliance plan is required to maintain Nasdaq listing.